Treatment outcomes of combined chemoradiation in locally advanced, unresectable non-small cell lung cancer: A single institution study

• Main Authors: Pitchayaponne Klunklin, Imjai Chitapanarux, Ekkasit Tharavichitkul, Somvilai Chakrabandhu, Wimrak Onchan, Bongkot Jia-Mahasap, Patumrat Sripan
• Format: Journal
• Published: 2018
• Subjects: Medicine
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85047152625&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/58947
• Institution: Chiang Mai University

© 2018, Medical Association of Thailand. All rights reserved. Objective: To report the outcomes of chemoradiation treatment in locally advanced non-small cell lung cancer [NSCLC] patients and determine the factors affecting survival. Materials and Methods: The medical records of 1,325 NSCLC patients treated with radiotherapy in our division between 2008 and 2013 were reviewed. The patient characteristics, the management characteristics, and outcome data were recorded and analyzed. Univariate and multivariate analysis were performed to identify the prognostic factor for overall survival [OS]. Results: One hundred three patients were included in the analysis. With a median follow-up time of 13.27 months, these patients had a median OS time of 21.4 months (95% CI 17.6 to 25.2) and median progression-free survival [PFS] time of 11.67 months (95% CI 9.69 to 13.65). The 2-year OS and PFS rate were 34.0% and 21.4%, respectively. For the patients treated by concurrent and sequential chemoradiation, the 2-year OS rates were 31.0% and 37.8% (p = 0.349) and the 2-year PFS rates were 24% and 20.6% (p = 0.690), respectively. The multivariate analysis revealed that age (hazard ratio [HR] 1.68, 95% CI 1.06 to 1.69) and stage (HR 2.13, 95% CI 1.43 to 3.39) were significant prognostic factors for OS. Conclusion: The treatment of locally advanced NSCLC in the authors’ hospital is feasible and the outcomes are comparable to others. The concurrent and sequential chemoradiation did not show any statistically significant difference in survival rate. The factors that associated with poor prognosis are age (older than 60 years) and stage (IIIB).